Showing 371-380 of 3239 results for "".
- Study: Plugging Immune Cell Leakage from Tumors Could Improve MelanomaTreatmenthttps://practicaldermatology.com/news/study-plugging-immune-cell-leakage-from-tumors-could-improve-melanomatreatment/2461578/The number of specialized immune cells available for fighting skin cancer double when a new treatment blocks their escape from melanoma tumors, according to new research out of NYU Langone Health’s Perlmutter Cancer Center Combining a chemical blocker of immune cell exit with
- Meet TargetCool, CoolHealth's Solution to Post-Procedure Pain, Bruisinghttps://practicaldermatology.com/news/meet-targetcool-coolhealths-solution-to-post-procedure-pain-bruising/2461549/CoolHealth is entering the U.S. market with TargetCool. Leveraging tuneable cooling technology, TargetCool rapidly cools the skin, allowing providers to specifically set a “target” skin temperature down to the exact degree and
- Dr. B Expands Telehealth Service into Dermatologyhttps://practicaldermatology.com/news/dr-b-expands-telehealth-service-into-dermatology/2461498/Telehealth service Dr. B added several specialties to it service network, including dermatology. The move allows patients to access low or no-cost virtual doctor consultations for a variety of conditions from home. Dr. B’s online consultation fee is $15 for paying p
- Topline Results: Union's Oral Orismilast Improves PASI by Week 16 in Patients with Moderate to Severe PsOhttps://practicaldermatology.com/news/topline-results-unions-oral-orismilast-improves-pasi-by-week-16-in-patients-with-moderate-to-severe-pso/2461489/Oral orismilast performed well in adult patients with moderate to severe psoriasis, according to topline results from the IASOS Phase 2b study. Data from the 202 patients randomized and dosed in the study showed that all active arms of oral orismilast achieved the primary endp
- Study: Isolated Nail PsO Not Linked to Metabolic Syndrome Riskhttps://practicaldermatology.com/news/study-isolated-nail-psoriasis-not-linked-to-metabolic-syndrome-risk/2461456/Isolated nail psoriasis does not increase risk for metabolic syndrome, according to a letter to the editor in the Journal of the European Academy of Dermatology & Venereology. The analysis include
- Report: AI Skin Technology on The Risehttps://practicaldermatology.com/news/report-ai-skin-technology-on-the-rise/2461428/Perfect Corp.’s latest Global Beauty Trend Report, “The Rise of AI Skin Technology” documents the rise in consumer interest in skin car
- Positive Results for Dermavant's Vtama in Pediatric Maximal Usage Study in Atopic Dermatitishttps://practicaldermatology.com/news/positive-results-for-dermavants-vtama-in-pediatric-maximal-usage-study-in-atopic-dermatitis/2461418/Dermavant Sciences shared positive results from its maximal usage study of Vtama (tapinarof) cream 1% in children down to age 2 years old with extensive burden of atopic dermatitis. “We are delighted with the results from our maximal usage study of Vtama cream 1% in atopic dermati
- Merz’s Xeomin Taps Teyana Taylor as Brand Partnerhttps://practicaldermatology.com/news/merzs-xeomin-taps-teyana-taylor-as-brand-partner/2461412/Teyana Taylor is the latest brand partner for Merz’z Xeomin (incobotulinumtoxinA). The U.S. partnership is a continuation of the ‘Beauty on Your Terms’ campaign for Xeomin, an FDA-approved double filtered anti-wrinkle injection to temporarily improve the appearanc
- Evommune Initiates Phase 2a Proof-of-Concept Clinical Trial of EVO101 in ADhttps://practicaldermatology.com/news/evommune-initiates-phase-2a-proof-of-concept-clinical-trial-of-evo101-in-ad/2461362/Evommune, Inc. enrolled the first patient in a Phase 2a proof-of-concept clinical trial evaluating EVO101, a novel small molecule inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4), in patients with atopic dermatitis (AD). The Phase 2a trial is a randomized, double-bl
- Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous BCChttps://practicaldermatology.com/news/sirnaomics-achieves-100-complete-response-in-phase-ii-clinical-trial-of-stp705-for-treatment-of-cutaneous-bcc/2461319/Patients receiving the 180μg dose level in the Phase II clinical trial of STP705 for the treatment of cutaneous basal cell carcinoma (BCC) achieved a 100% complete response, with no safety signals, Sirnaomics reports. STP705 is a siRNA (small inte